Measles virus vaccine expressing SARS-COV-2 protein(s)
View Patent ↗A recombinant measles viral vector comprising a nucleic acid sequence encoding a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein is provided. Polypeptides comprising the SARS-CoV-2 spike glycoprotein also are provided, as well as related nucleic acids, vectors, and compositions. The polypeptides, nucleic acids, vectors, and compositions can be used in methods of preventing, inhibiting, reducing, eliminating, protecting, or delaying the onset of an infection or an infectious clinical condition caused by coronavirus and methods for inducing an immune response against a coronavirus.
1. A recombinant measles viral vector comprising a nucleic acid sequence encoding a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein, wherein the nucleic acid sequence contains at least one modification that disrupts the endoplasmic reticulum (ER) retention sequence of the SARS-CoV-2 spike glycoprotein.
2. The recombinant measles viral vector of claim 1 , wherein the ER retention sequence of the SARS-CoV-2 spike glycoprotein contains AxAxx rather than KxHxx in the cytoplasmic tail.
3. The recombinant measles viral vector of claim 1 , wherein the nucleic acid sequence encoding the SARS-CoV-2 spike glycoprotein is SEQ ID NO: 3 (S-CO-AA).
4. The recombinant measles viral vector of claim 1 , wherein the amino acid sequence of the SARS-CoV-2 spike glycoprotein is SEQ ID NO: 10 (S-CO-AA).
5. The recombinant measles viral vector of claim 1 , comprising the nucleic acid sequence of SEQ ID NO: 17 (SARS-CoV-2-S-CO-AA).
6. A pharmaceutical composition comprising the recombinant measles viral vector of claim 1 and a pharmaceutically acceptable carrier.
7. A nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 (S-CO-AA).
8. A nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 3 (S-CO-AA).
9. A recombinant vector comprising the nucleic acid of claim 7 .
10. A pharmaceutical composition comprising (i) the nucleic acid of claim 7 and (ii) a pharmaceutically acceptable carrier.